子宫肌瘤全子宫切除术中西医结合临床路径的构建和评价性研究
|
摘要
背景
如何使病人用低廉的费用享受到优质的医疗护理服务,满足以“病人为中心”的要求和高质量有效率的医疗服务,已成为卫生行业的重大课题。医护管理者必须思考如何在医疗服务过程中,让病人最大限度地合理使用“医疗费用”。针对某一病种和手术采取临床路径是一种行之有效的途径,可以达到改善病人服务和有效利用卫生资源的目的。临床路径(Clinical Pathways, CP)是一种诊疗标准化方法,以缩短平均住院日、合理支付医疗费用为特征,按病种设计最佳的医疗和护理方案,根据病情合理安排住院时间和费用。业已证实临床路径不仅能有效降低住院时间和住院费用,同时也能显著提高医疗服务质量,受到各国医学界的重视,成为21世纪以来的一种崭新的医疗模式。
子宫肌瘤全子宫切除病人因住院天数长、住院费用高,给社会和家庭带来了沉重的医疗费用负担。如何规范住院管理流程,在保证医疗质量的前提下,缩短住院天数,降低住院费用,已成为当务之急。本课题通过构建子宫肌瘤全子宫切除术中西医结合临床路径,探讨中医院构建临床路径的方法,对于提高其中西医结合治疗水平和卫生管理方法,不断提高医疗服务质量和水平,构建和谐医患关系具有重要意义。
目的
(一)根据临床路径构建的科学性原则,对子宫肌瘤全子宫切除术具有中西医结合特色的诊疗方案进行优化,初步形成证据充分、共识度高、推广性强的诊疗方案,为临床路径的构建提供核心内容。
(二)对子宫肌瘤全宫切除术临床路径进行临床观察,通过与回顾性病案分析结果的比较,客观评价子宫肌瘤全子宫切除术中西医结合临床路径的临床效益,为子宫肌瘤全子宫切除术中西医结合临床路径的推广提供科学依据。
内容与方法
本研究为两部分,第一部分研究重点在于运用专家咨询方法对子宫肌瘤全子宫切除术诊疗方案进行优化,为临床路径的构建提供核心内容。第二部分研究是采用非同期非随机研究方法对构建的子宫肌瘤全子宫切除术中西医结合临床路径进行了临床观察,与回顾性病案统计结果进行对照研究,对该路径治疗方案有效性进行评估。
(一)子宫肌瘤全子宫切除术中西医结合临床路径构建的优化研究
1专家咨询研究
针对共识度较低、尚无充分文献证据支持的诊疗措施进行专家咨询。制定专家咨询问卷,选择国内中医或中西医结合专家以书面的形式进行咨询。通过两轮咨询后,征求专家的认可意见,形成诊疗方案。
2在优化的诊疗方案的基础上构建临床路径
结合我院回顾性研究结果,确定临床路径的管理时限和时间点,制定路径纳入标准、排除标准。设计路径实施流程图。根据2009年卫生部下发的临床路径实施方案,制定子宫肌瘤全子宫切除术临床路径表单。
(二)子宫肌瘤全子宫切除术中西医结合临床路径的临床观察研究
收集2009年1月至2010年10月6家医院纳入临床路径的子宫肌瘤患者,共450例作为路径组,其中行腹式全宫病人376例,阴式全宫27例,腹腔镜手术42例,退出5蒯。同时纳入该6家医院的2007年1月至2008年12月符合回顾性纳入标准的连续性病例544例为回顾组,其中行腹式全宫病人487例,阴式全宫9例,腹腔镜手术48例。运用临床流行病学/DME方法,进行回顾性和路径性对照研究,对子宫肌瘤全宫切除术中西医结合优化治疗方案的有效性进行评估。
结果
(一)专家咨询研究
通过两轮专家咨询,两次咨询表回收率均为100%,根据两轮专家咨询意见,对1个二级指标、15个条目进行了修改,初步形成了3个一级指标,8个二级指标共28个条目。
(二)子宫肌瘤全宫切除术临床路径评价研究
1临床路径对各术式平均住院天数影响比较
1.1腹式全宫
回顾组平均住院天数11.77±3.79天,路径组平均住院天数10.57±2.05天,两组平均住院天数比较,差异有统计学差异(P<0.05)。
1.2阴式全宫
回顾组平均平均住院天数9.5±3.89天,路径组平均住院天数8.81±2.06天,两组平均住院天数比较,差异有统计学差异(P<0.05)。
1.3腹腔镜全宫
回顾组平均住院天数10.77±2.31天,路径组平均住院天数9.33±1.97天,两组平均住院天数比较,差异有统计学差异(P<0.05)。
各术式临床路径组平均住院时间与回顾组相比较,差异有统计学意义(P<0.05),说明临床路径能更有效的降低住院时间。
2临床路径对各术式住院费用影响比较
2.1腹式全宫
平均住院总费用：回顾组为9385.50±2047.67元,路径组为9024.41±2902.47元,两组住院费用比较,差异有统计学意义(P<0.05)；西药费：回顾组为1225.17±837.47元,路径组为1310.46±674.98元,两组西药费用比较,差异有统计学意义(P<0.05)；检查费：回顾组为413.70±358.09元,路径组为316.04±235.47元,两组检查费用比较,差异有统计学意义(P<0.05)；治疗费：回顾组为1735.28±920.34元,路径组为1221.48±606.62元,两组治疗费用比较,差异有统计学意义(P<0.05)。
2.2阴式全宫
平均住院总费用：回顾组为7728.16±1934.25元,路径组为9111.9674±2533.95元,两组住院费用比较,差异无统计学意义(P>0.05)；西药费：回顾组为1254.81±306.73元,路径组为1172.50±375.25元,两组西药费用比较,差异有统计学意义(P<0.05)；检查费：回顾组为359.06±299.18元,路径组为315.11±303.82元,两组检查费用比较,差异有统计学意义(P<0.05)；治疗费：回顾组为1214.06±769.44元,路径组为1002.59±593.47元,两组治疗费用比较,差异有统计学意义(P<0.05)。
2.3腹腔镜全宫
平均住院总费用：回顾组为9154.05±1749.86元,路径组为12497.68±3238.05元,两组住院费用比较无统计学意义(P>0.05)；西药费：回顾组为1049.86±604.27元,路径组为1703.48±670.85元,两组西药费用比较,差异无统计学意义(P>0.05)；检查费：回顾组为403.43±304.89元,路径组为358.23±189.83元,两组检查费用比较,差异有统计学意义(P<0.05)；治疗费：回顾组为1548.89±595.58元,路径组为1807.49±1280.92元,两组治疗费用比较无统计学意义(P>0.05)。
3临床路径对各术式术后恢复指标比较
3.1腹式全宫
首次下床活动时间：回顾组为46.21±11.35小时,路径组为33.56±9.58小时,两组在首次下床活动时间比较,差异有统计学意义(P<0.05)；排气时间：回顾组为51.62±12.33小时,路径组为43.71±13.58小时,两组在排气时间比较,差异有统计学意义(P<0.05)；排便时间：回顾组为90.70±22.89小时,路径组为77.25±24.02小时,两组在排便时间比较,差异有统计学意义(P<0.05)。
3.2阴式全宫
首次下床活动时间：回顾组为31.29±7.53小时,路径组为26.53±7.14小时,两组在首次下床活动时间比较,差异有统计学意义(P<0.05)；排气时间：回顾组为42.58±11.93小时,路径组为35.37±12.31小时,两组在排气时间比较,差异有统计学意义(P<0.05)；排便时间：回顾组为88.26±25.76小时,路径组为74.59±19.79小时,两组在排便时间比较,差异有统计学意义(P<0.05)。
3.3腹腔镜全宫
首次下床活动时间：回顾组为32.14±9.56小时,路径组为28.45±8.43小时,两组在首次下床活动时间比较,差异有统计学意义(P<0.05)；排气时间：回顾组为49.41±12.78小时,路径组为36.42±13.71小时,两组在排气时间比较,差异有统计学意义(P<0.05);排便时间：回顾组为84.91±18.31小时,路径组为69.38±24.13小时,两组在排便时间比较,差异有统计学意义(P<0.05)。
3.4临床路径对各术式术后并发症的影响
各术式路径组病人在术后并发症发生率上明显低于回顾组,差异有统计学意义(P<0.05)。
3.5临床路径对路径组满意度调查的影响
病人对医疗过程、等候时间、服务态度及整体满意度均较高,各项满意度均达到95%以上,总体满意度为97.55%。
3.6路径组变异调查
450例子宫肌瘤全子宫切除病例中,通过对变异来源的统计分析,得出目前变异种类按发生率由高到低的排序为：医务人员39.3%(177/450)>医院系统22.2%(100/450)>病人需求20%(90/450)>疾病转归10.2%(46/450)>退出1%(5/450)。按照对变异的管理难易分类,可控变异的发生率较高,为61.6%(277/450)。
结论
(一)子宫肌瘤全子宫切除术中西医结合临床路径的核心是具有中西医特色的诊疗方案。本研究在既往文献研究及科室经验基础上通过专家咨询研究,初步确定了子宫肌瘤全子宫切除中西医诊疗方案。该方案主要包括路径执行、疗效评价、效率评价、围手术期中医药治疗部分。对子宫肌瘤全子宫切除术式选择标准、抗生素应用时间、术后中医治疗、路径疗效及效率评价等指标进行了确定。
(二)在优化方案的基础上,结合我院回顾性研究及国家卫生部发布的路径表单格式,制定路径目标人群及退出路径标准,路径总时限,路径实施流程。完成路径表单。
(三)实施临床路径,规范了我们的住院管理流程,减少住院费用(主要是腹式)、缩短住院天数,同时病人术后胃肠功能恢复状态改善明显,减少术后并发症,提高病人满意度。
Object ives
How to make the patient enjoys the superior quality of the medical treatment nursing service by the cheap expenses, satisfy "take patient as the center" of request and high quantity serve efficiently, have become an important topic of the health profession.The governor must consider how to let the patient reasonable to use "the medical treatment expenses" with maximum limit throught the medical treatment service process. Aim at the some disease grows to adopt with surgical operation, the clinical pathway is a valid path to get the purposes of improving the serve for patient and making use of the health resources effectively. Clinical pathways(CP) is a standardization method of diagnose and treat, and its main charceteristics is to shorten average hospitalization days and pay medical cost reasonably, to design the most reasonale medical and nurse scheme by entity, to arrange the hospitalization days and medical cost reasonably and to improve medical service quality. Every country has pay attention to the use of CP, and CP has become a new medical mode in new century.
The patients of the panhysterectomy, with long and complex course, often has longer inpatient days, higher hospital expense. Shaping the clinical pathway, to standard hospital management process, short inpatient days, reduce hospitalization fees, has become a top priority.
It has a great significance to educe dominance of western medicine and Chinese medicine by constructing panhysterectomy clinical pathways of integrated traditional Chinese and western medicine, to explore the construction method of panhysterectomy inhospital of traditional Chinese medicine, to improve the therapy level of integrated traditional Chinese and western medicine, methods of health supervision, quality and level of medical service.
Research purposes
1. According to the scientific principle of clinical pathway consruction, we optimized the TCM diagnosis scheme of panhysterectomy, and initially formed a TCM therapy with high degree of consensus, sufficient evidence, and powerful generalization, for providing the core content of clinical pathway.
2. With preliminary clinical observation of panhysterectomy pathway, we preliminary discuss clinical effect of panhysterectomy clinical pathway of nondialytic period, Which provide a basis for the form to the A panhysterectomy clinical pathway with integrated Chinese and Western Medicine.
Research content
This research is divided into two parts. The first part of the research focuses optimization of panhysterectomy nondialytic treatment scheme of TCM. The second part of the research is to carry on the preliminary clinical observation of panhysterectomy combine traditional Chinese and western medicine clinical pathway.
1. Constructing optinal research of clinical pathway
With regard to the retrospective study results, we determine the management time of clinical pathway, and formulate inclusion and exclusion criteria, and then design implamentation flow path. According to the clinical pathway issued by health ministry 2009, we formulate clinical pathway of panhysterectomy of nondialytic period.
2. Clinical observation research of clinical pathway
We collect six hospitals about 450 patients with panhysterectomy of clinical pathway from December of 2009 to October in 2010, which content 376 cases of TAH、27 cases of TVA、42 cases of LH, withdrow 5cases. Also we included 544 cases records with path into standard from the serial of January 2007 to December 2008 in the hospitals, which content 487 cases of TAH、9 cases of TVA and 48 cases of LH. and analysis the record number, hospitalization costand improved hospital lab index before hospitalization and after. Through the comparison, we discussed the clinical benefits of clinical pathway.The efficacy of the optimized management of Integrated Chinese and Western Medicine for patients with panhysterectomy was evaluated by retrospective and prospective controllled study according to clinical epidemiology or DME approach.
Research results
1.The research of expert consultation
The results showed that the respond rates of the two expert consul tation was both 100%. After the two-round meetings, one second-class indicators was modified and 15 items were revised. At last, the 28-items were developed which covers 3-first-class indicators and 8-second-class indicators.
2. Assessment on Clinical Pathway of the panhysterectomy
2.1 The effect of CP on length of stay in different surgery type:
(1) TAH
There was statistically significant difference between retrospective group and CP group in the average hospitals day(11.77±3.79days vs.10.57±2.05days,P<0.05).
(2) TVA
The comparison between retrospective group and CP group in the average hospitals day showed statistically significant difference (9.5±3.89days vs.8.81±2.06days, P<0.05).
(3) LH
The comparison between retrospective group and CP group in the average hospitals day showed statistically significant difference (10.77±2.31days vs.9.33±1.97days, P<0.05). there was statistical difference in total length of stay between CP group and retrospective group (P<0.05) in the different suegical type. It mean that CP could reduce length of day.
2.2 The effect of CP on hospitalization expenses
(1) TAH
The average total expenses:The comparison between retrospective group and CP group in average total expenses showed statistically significant difference(9385.50±2047.67Yuan vs.9024.41±2902.47 Yuan, P<0.05); medicine expenses:There was statistically significant difference between two groups (1225.17±837.47Yuan vs.1310.46±674.98 Yuan, P<0.05);check fee:The comparison between retrospective group and CP group in check fee showed statistically significant difference(413.70±358.09Yuan vs.316.04±235.47 Yuan, P<0.05);cure expenses:There was statistically significant difference between two groups in cure expenses (1735.28±920.34Yuan vs.1221.48±606.62 Yuan, P<0.05).
(2) TVA
The average total expenses:The comparison between retrospective group and CP group in average total expenses showed statistically significant difference(7728.16±1934.25Yuan vs.9111.9674±2533.95 Yuan, P<0.05); medicine expenses:There was statistically significant difference between two groups (1254.81±306.73Yuan vs.1172.50±375.25Yuan(P<0.05);check fee:The comparison between retrospective group and CP group in check fee showed statistically significant difference (359.06±299.18Yuan vs.315.11±303.82Yuan, P<0.05); cure expenses:There was statistically significant difference between two groups in cure expenses (1214.06±769.44Yuan vs.1002.59±593.47Yuan, P<0.05).
(3-) LH
The average total expenses:The comparison between retrospective group and CP group in average total expenses showed statistically significant difference (9154.05±1749.86Yuan vs.12497.68±3238.05 Yuan, P<0.05); medicine expenses:There was no statistically significant difference between two groups (1049.86±604.27Yuan vs.1703.48±670.85 Yuan, P>0.05);check fee:The comparison between retrospective group and CP group in check fee showed statistically significant difference(403.43±304.89Yuan vs.358.23±189.83Yuan, P<0.05); cure expenses:There was no statistically significant difference between two groups in cure expenses (1548.89±595.58Yuan vs.1807.49±1280.92Yuan, P>0.05)
2.3 The effect of CP on recovery of gastrointestinal function:
(1) TAH
First bad time:The comparison between retrospective group and CP group in First bad time showed statistically significant difference
(46.21±11.35hour vs.33.56±9.58 hour, P<0.05); first exhaust time: There was statistically significant difference between two groups in first exhaust time (51.62±12.33hour vs.43.71±13.58hour, P<0.05); first defecate time:There was statistically significant difference between two groups in first defecate time (90.70±22.89hour vs.77.25±24.02hour, P<0.05).
(2) TVA
First bad time:The comparison between retrospective group and CP group in First bad time showed statistically significant difference (31.29±7.53hour vs.26.53±7.14hour, P<0.05); first exhaust time:There was statistically significant difference between two groups in first exhaust time (42.58±11.93hour vs.35.37±12.31hour, P<0.05); first defecate time:There was statistically significant difference between two groups in first defecate time (88.26±25.76hour vs.74.59±19.79hour, P<0.05).
(3) LH
First bad time:The comparison between retrospective group and CP group in First bad time showed statistically significant difference (32.14±9.56hour vs.28.45±8.43hour, P<0.05); first exhaust time:There was statistically significant difference between two groups in first exhaust time (49.41±12.78hour vs.36.42±13.71hour, P<0.05); first defecate time:There was statistically significant difference between two groups in first defecate time (84.91±18.31hour vs.69.38±24.13hour, P<0.05).
2.4 The effect of CP on postoperative complications:There was statistieal difference between two groups in complitions (P<0.05)
2.5 the result of satisfaction survey:The patients are satisfy at every item, the total satisfaction reach to 97.55%.
2.6 The result of CP on variance:In 450 cases, Through the statistical analysis of the variances, it was found that the incidence of variance categories in present research which ranged from high to low practitioners 27.1%(122/450)>hospital system22.2%(100/450)>patients' requirements20%(90/450)>disease progress 10.2%(46/450)>and withd rawcases1%(5/450). The incidence of the controllable variances were higher incidence of the controllable variances were higher (25.50%(38/149)) than the uneontrollable, according to the manage ability of variance62.01%(142/229).
Conclusion
1. The core of the clinical pathway is the treatment scheme which has the characteristics of intergrated Chinese and Western Medicine.The research through expert consultation which based on literature research and clinical experience of department preliminary made of therapy, which include implement of CP、the evalution of effection、the evalution of efficiency and the part of perioperative medical treatment. We preliminary determine the surgical selection criteria、the time of using antibiatics、Chinese medicine treatment after surgery、efficacy and efficiency evaluation.
2. With regard to the retrospective study, we determine target population and the exit criteria of path, total path time limit, implement processes of path on the basis of optimized seheme. Also we form path form, according to pathform format issued by the state ministry.
3. The clinical pathway regulates the management of our hospital process, reduces hospital expenses (main reduce the expenses of TAH);shortens hospitalization days, improves patient clinical symptoms; ensure the quality of medical treatment. Explanation of clinical pathway standardized management and strengthen the characteristies of the application.
如何使病人用低廉的费用享受到优质的医疗护理服务,满足以“病人为中心”的要求和高质量有效率的医疗服务,已成为卫生行业的重大课题。医护管理者必须思考如何在医疗服务过程中,让病人最大限度地合理使用“医疗费用”。针对某一病种和手术采取临床路径是一种行之有效的途径,可以达到改善病人服务和有效利用卫生资源的目的。临床路径(Clinical Pathways, CP)是一种诊疗标准化方法,以缩短平均住院日、合理支付医疗费用为特征,按病种设计最佳的医疗和护理方案,根据病情合理安排住院时间和费用。业已证实临床路径不仅能有效降低住院时间和住院费用,同时也能显著提高医疗服务质量,受到各国医学界的重视,成为21世纪以来的一种崭新的医疗模式。
子宫肌瘤全子宫切除病人因住院天数长、住院费用高,给社会和家庭带来了沉重的医疗费用负担。如何规范住院管理流程,在保证医疗质量的前提下,缩短住院天数,降低住院费用,已成为当务之急。本课题通过构建子宫肌瘤全子宫切除术中西医结合临床路径,探讨中医院构建临床路径的方法,对于提高其中西医结合治疗水平和卫生管理方法,不断提高医疗服务质量和水平,构建和谐医患关系具有重要意义。
目的
(一)根据临床路径构建的科学性原则,对子宫肌瘤全子宫切除术具有中西医结合特色的诊疗方案进行优化,初步形成证据充分、共识度高、推广性强的诊疗方案,为临床路径的构建提供核心内容。
(二)对子宫肌瘤全宫切除术临床路径进行临床观察,通过与回顾性病案分析结果的比较,客观评价子宫肌瘤全子宫切除术中西医结合临床路径的临床效益,为子宫肌瘤全子宫切除术中西医结合临床路径的推广提供科学依据。
内容与方法
本研究为两部分,第一部分研究重点在于运用专家咨询方法对子宫肌瘤全子宫切除术诊疗方案进行优化,为临床路径的构建提供核心内容。第二部分研究是采用非同期非随机研究方法对构建的子宫肌瘤全子宫切除术中西医结合临床路径进行了临床观察,与回顾性病案统计结果进行对照研究,对该路径治疗方案有效性进行评估。
(一)子宫肌瘤全子宫切除术中西医结合临床路径构建的优化研究
1专家咨询研究
针对共识度较低、尚无充分文献证据支持的诊疗措施进行专家咨询。制定专家咨询问卷,选择国内中医或中西医结合专家以书面的形式进行咨询。通过两轮咨询后,征求专家的认可意见,形成诊疗方案。
2在优化的诊疗方案的基础上构建临床路径
结合我院回顾性研究结果,确定临床路径的管理时限和时间点,制定路径纳入标准、排除标准。设计路径实施流程图。根据2009年卫生部下发的临床路径实施方案,制定子宫肌瘤全子宫切除术临床路径表单。
(二)子宫肌瘤全子宫切除术中西医结合临床路径的临床观察研究
收集2009年1月至2010年10月6家医院纳入临床路径的子宫肌瘤患者,共450例作为路径组,其中行腹式全宫病人376例,阴式全宫27例,腹腔镜手术42例,退出5蒯。同时纳入该6家医院的2007年1月至2008年12月符合回顾性纳入标准的连续性病例544例为回顾组,其中行腹式全宫病人487例,阴式全宫9例,腹腔镜手术48例。运用临床流行病学/DME方法,进行回顾性和路径性对照研究,对子宫肌瘤全宫切除术中西医结合优化治疗方案的有效性进行评估。
结果
(一)专家咨询研究
通过两轮专家咨询,两次咨询表回收率均为100%,根据两轮专家咨询意见,对1个二级指标、15个条目进行了修改,初步形成了3个一级指标,8个二级指标共28个条目。
(二)子宫肌瘤全宫切除术临床路径评价研究
1临床路径对各术式平均住院天数影响比较
1.1腹式全宫
回顾组平均住院天数11.77±3.79天,路径组平均住院天数10.57±2.05天,两组平均住院天数比较,差异有统计学差异(P<0.05)。
1.2阴式全宫
回顾组平均平均住院天数9.5±3.89天,路径组平均住院天数8.81±2.06天,两组平均住院天数比较,差异有统计学差异(P<0.05)。
1.3腹腔镜全宫
回顾组平均住院天数10.77±2.31天,路径组平均住院天数9.33±1.97天,两组平均住院天数比较,差异有统计学差异(P<0.05)。
各术式临床路径组平均住院时间与回顾组相比较,差异有统计学意义(P<0.05),说明临床路径能更有效的降低住院时间。
2临床路径对各术式住院费用影响比较
2.1腹式全宫
平均住院总费用：回顾组为9385.50±2047.67元,路径组为9024.41±2902.47元,两组住院费用比较,差异有统计学意义(P<0.05)；西药费：回顾组为1225.17±837.47元,路径组为1310.46±674.98元,两组西药费用比较,差异有统计学意义(P<0.05)；检查费：回顾组为413.70±358.09元,路径组为316.04±235.47元,两组检查费用比较,差异有统计学意义(P<0.05)；治疗费：回顾组为1735.28±920.34元,路径组为1221.48±606.62元,两组治疗费用比较,差异有统计学意义(P<0.05)。
2.2阴式全宫
平均住院总费用：回顾组为7728.16±1934.25元,路径组为9111.9674±2533.95元,两组住院费用比较,差异无统计学意义(P>0.05)；西药费：回顾组为1254.81±306.73元,路径组为1172.50±375.25元,两组西药费用比较,差异有统计学意义(P<0.05)；检查费：回顾组为359.06±299.18元,路径组为315.11±303.82元,两组检查费用比较,差异有统计学意义(P<0.05)；治疗费：回顾组为1214.06±769.44元,路径组为1002.59±593.47元,两组治疗费用比较,差异有统计学意义(P<0.05)。
2.3腹腔镜全宫
平均住院总费用：回顾组为9154.05±1749.86元,路径组为12497.68±3238.05元,两组住院费用比较无统计学意义(P>0.05)；西药费：回顾组为1049.86±604.27元,路径组为1703.48±670.85元,两组西药费用比较,差异无统计学意义(P>0.05)；检查费：回顾组为403.43±304.89元,路径组为358.23±189.83元,两组检查费用比较,差异有统计学意义(P<0.05)；治疗费：回顾组为1548.89±595.58元,路径组为1807.49±1280.92元,两组治疗费用比较无统计学意义(P>0.05)。
3临床路径对各术式术后恢复指标比较
3.1腹式全宫
首次下床活动时间：回顾组为46.21±11.35小时,路径组为33.56±9.58小时,两组在首次下床活动时间比较,差异有统计学意义(P<0.05)；排气时间：回顾组为51.62±12.33小时,路径组为43.71±13.58小时,两组在排气时间比较,差异有统计学意义(P<0.05)；排便时间：回顾组为90.70±22.89小时,路径组为77.25±24.02小时,两组在排便时间比较,差异有统计学意义(P<0.05)。
3.2阴式全宫
首次下床活动时间：回顾组为31.29±7.53小时,路径组为26.53±7.14小时,两组在首次下床活动时间比较,差异有统计学意义(P<0.05)；排气时间：回顾组为42.58±11.93小时,路径组为35.37±12.31小时,两组在排气时间比较,差异有统计学意义(P<0.05)；排便时间：回顾组为88.26±25.76小时,路径组为74.59±19.79小时,两组在排便时间比较,差异有统计学意义(P<0.05)。
3.3腹腔镜全宫
首次下床活动时间：回顾组为32.14±9.56小时,路径组为28.45±8.43小时,两组在首次下床活动时间比较,差异有统计学意义(P<0.05)；排气时间：回顾组为49.41±12.78小时,路径组为36.42±13.71小时,两组在排气时间比较,差异有统计学意义(P<0.05);排便时间：回顾组为84.91±18.31小时,路径组为69.38±24.13小时,两组在排便时间比较,差异有统计学意义(P<0.05)。
3.4临床路径对各术式术后并发症的影响
各术式路径组病人在术后并发症发生率上明显低于回顾组,差异有统计学意义(P<0.05)。
3.5临床路径对路径组满意度调查的影响
病人对医疗过程、等候时间、服务态度及整体满意度均较高,各项满意度均达到95%以上,总体满意度为97.55%。
3.6路径组变异调查
450例子宫肌瘤全子宫切除病例中,通过对变异来源的统计分析,得出目前变异种类按发生率由高到低的排序为：医务人员39.3%(177/450)>医院系统22.2%(100/450)>病人需求20%(90/450)>疾病转归10.2%(46/450)>退出1%(5/450)。按照对变异的管理难易分类,可控变异的发生率较高,为61.6%(277/450)。
结论
(一)子宫肌瘤全子宫切除术中西医结合临床路径的核心是具有中西医特色的诊疗方案。本研究在既往文献研究及科室经验基础上通过专家咨询研究,初步确定了子宫肌瘤全子宫切除中西医诊疗方案。该方案主要包括路径执行、疗效评价、效率评价、围手术期中医药治疗部分。对子宫肌瘤全子宫切除术式选择标准、抗生素应用时间、术后中医治疗、路径疗效及效率评价等指标进行了确定。
(二)在优化方案的基础上,结合我院回顾性研究及国家卫生部发布的路径表单格式,制定路径目标人群及退出路径标准,路径总时限,路径实施流程。完成路径表单。
(三)实施临床路径,规范了我们的住院管理流程,减少住院费用(主要是腹式)、缩短住院天数,同时病人术后胃肠功能恢复状态改善明显,减少术后并发症,提高病人满意度。
Object ives
How to make the patient enjoys the superior quality of the medical treatment nursing service by the cheap expenses, satisfy "take patient as the center" of request and high quantity serve efficiently, have become an important topic of the health profession.The governor must consider how to let the patient reasonable to use "the medical treatment expenses" with maximum limit throught the medical treatment service process. Aim at the some disease grows to adopt with surgical operation, the clinical pathway is a valid path to get the purposes of improving the serve for patient and making use of the health resources effectively. Clinical pathways(CP) is a standardization method of diagnose and treat, and its main charceteristics is to shorten average hospitalization days and pay medical cost reasonably, to design the most reasonale medical and nurse scheme by entity, to arrange the hospitalization days and medical cost reasonably and to improve medical service quality. Every country has pay attention to the use of CP, and CP has become a new medical mode in new century.
The patients of the panhysterectomy, with long and complex course, often has longer inpatient days, higher hospital expense. Shaping the clinical pathway, to standard hospital management process, short inpatient days, reduce hospitalization fees, has become a top priority.
It has a great significance to educe dominance of western medicine and Chinese medicine by constructing panhysterectomy clinical pathways of integrated traditional Chinese and western medicine, to explore the construction method of panhysterectomy inhospital of traditional Chinese medicine, to improve the therapy level of integrated traditional Chinese and western medicine, methods of health supervision, quality and level of medical service.
Research purposes
1. According to the scientific principle of clinical pathway consruction, we optimized the TCM diagnosis scheme of panhysterectomy, and initially formed a TCM therapy with high degree of consensus, sufficient evidence, and powerful generalization, for providing the core content of clinical pathway.
2. With preliminary clinical observation of panhysterectomy pathway, we preliminary discuss clinical effect of panhysterectomy clinical pathway of nondialytic period, Which provide a basis for the form to the A panhysterectomy clinical pathway with integrated Chinese and Western Medicine.
Research content
This research is divided into two parts. The first part of the research focuses optimization of panhysterectomy nondialytic treatment scheme of TCM. The second part of the research is to carry on the preliminary clinical observation of panhysterectomy combine traditional Chinese and western medicine clinical pathway.
1. Constructing optinal research of clinical pathway
With regard to the retrospective study results, we determine the management time of clinical pathway, and formulate inclusion and exclusion criteria, and then design implamentation flow path. According to the clinical pathway issued by health ministry 2009, we formulate clinical pathway of panhysterectomy of nondialytic period.
2. Clinical observation research of clinical pathway
We collect six hospitals about 450 patients with panhysterectomy of clinical pathway from December of 2009 to October in 2010, which content 376 cases of TAH、27 cases of TVA、42 cases of LH, withdrow 5cases. Also we included 544 cases records with path into standard from the serial of January 2007 to December 2008 in the hospitals, which content 487 cases of TAH、9 cases of TVA and 48 cases of LH. and analysis the record number, hospitalization costand improved hospital lab index before hospitalization and after. Through the comparison, we discussed the clinical benefits of clinical pathway.The efficacy of the optimized management of Integrated Chinese and Western Medicine for patients with panhysterectomy was evaluated by retrospective and prospective controllled study according to clinical epidemiology or DME approach.
Research results
1.The research of expert consultation
The results showed that the respond rates of the two expert consul tation was both 100%. After the two-round meetings, one second-class indicators was modified and 15 items were revised. At last, the 28-items were developed which covers 3-first-class indicators and 8-second-class indicators.
2. Assessment on Clinical Pathway of the panhysterectomy
2.1 The effect of CP on length of stay in different surgery type:
(1) TAH
There was statistically significant difference between retrospective group and CP group in the average hospitals day(11.77±3.79days vs.10.57±2.05days,P<0.05).
(2) TVA
The comparison between retrospective group and CP group in the average hospitals day showed statistically significant difference (9.5±3.89days vs.8.81±2.06days, P<0.05).
(3) LH
The comparison between retrospective group and CP group in the average hospitals day showed statistically significant difference (10.77±2.31days vs.9.33±1.97days, P<0.05). there was statistical difference in total length of stay between CP group and retrospective group (P<0.05) in the different suegical type. It mean that CP could reduce length of day.
2.2 The effect of CP on hospitalization expenses
(1) TAH
The average total expenses:The comparison between retrospective group and CP group in average total expenses showed statistically significant difference(9385.50±2047.67Yuan vs.9024.41±2902.47 Yuan, P<0.05); medicine expenses:There was statistically significant difference between two groups (1225.17±837.47Yuan vs.1310.46±674.98 Yuan, P<0.05);check fee:The comparison between retrospective group and CP group in check fee showed statistically significant difference(413.70±358.09Yuan vs.316.04±235.47 Yuan, P<0.05);cure expenses:There was statistically significant difference between two groups in cure expenses (1735.28±920.34Yuan vs.1221.48±606.62 Yuan, P<0.05).
(2) TVA
The average total expenses:The comparison between retrospective group and CP group in average total expenses showed statistically significant difference(7728.16±1934.25Yuan vs.9111.9674±2533.95 Yuan, P<0.05); medicine expenses:There was statistically significant difference between two groups (1254.81±306.73Yuan vs.1172.50±375.25Yuan(P<0.05);check fee:The comparison between retrospective group and CP group in check fee showed statistically significant difference (359.06±299.18Yuan vs.315.11±303.82Yuan, P<0.05); cure expenses:There was statistically significant difference between two groups in cure expenses (1214.06±769.44Yuan vs.1002.59±593.47Yuan, P<0.05).
(3-) LH
The average total expenses:The comparison between retrospective group and CP group in average total expenses showed statistically significant difference (9154.05±1749.86Yuan vs.12497.68±3238.05 Yuan, P<0.05); medicine expenses:There was no statistically significant difference between two groups (1049.86±604.27Yuan vs.1703.48±670.85 Yuan, P>0.05);check fee:The comparison between retrospective group and CP group in check fee showed statistically significant difference(403.43±304.89Yuan vs.358.23±189.83Yuan, P<0.05); cure expenses:There was no statistically significant difference between two groups in cure expenses (1548.89±595.58Yuan vs.1807.49±1280.92Yuan, P>0.05)
2.3 The effect of CP on recovery of gastrointestinal function:
(1) TAH
First bad time:The comparison between retrospective group and CP group in First bad time showed statistically significant difference
(46.21±11.35hour vs.33.56±9.58 hour, P<0.05); first exhaust time: There was statistically significant difference between two groups in first exhaust time (51.62±12.33hour vs.43.71±13.58hour, P<0.05); first defecate time:There was statistically significant difference between two groups in first defecate time (90.70±22.89hour vs.77.25±24.02hour, P<0.05).
(2) TVA
First bad time:The comparison between retrospective group and CP group in First bad time showed statistically significant difference (31.29±7.53hour vs.26.53±7.14hour, P<0.05); first exhaust time:There was statistically significant difference between two groups in first exhaust time (42.58±11.93hour vs.35.37±12.31hour, P<0.05); first defecate time:There was statistically significant difference between two groups in first defecate time (88.26±25.76hour vs.74.59±19.79hour, P<0.05).
(3) LH
First bad time:The comparison between retrospective group and CP group in First bad time showed statistically significant difference (32.14±9.56hour vs.28.45±8.43hour, P<0.05); first exhaust time:There was statistically significant difference between two groups in first exhaust time (49.41±12.78hour vs.36.42±13.71hour, P<0.05); first defecate time:There was statistically significant difference between two groups in first defecate time (84.91±18.31hour vs.69.38±24.13hour, P<0.05).
2.4 The effect of CP on postoperative complications:There was statistieal difference between two groups in complitions (P<0.05)
2.5 the result of satisfaction survey:The patients are satisfy at every item, the total satisfaction reach to 97.55%.
2.6 The result of CP on variance:In 450 cases, Through the statistical analysis of the variances, it was found that the incidence of variance categories in present research which ranged from high to low practitioners 27.1%(122/450)>hospital system22.2%(100/450)>patients' requirements20%(90/450)>disease progress 10.2%(46/450)>and withd rawcases1%(5/450). The incidence of the controllable variances were higher incidence of the controllable variances were higher (25.50%(38/149)) than the uneontrollable, according to the manage ability of variance62.01%(142/229).
Conclusion
1. The core of the clinical pathway is the treatment scheme which has the characteristics of intergrated Chinese and Western Medicine.The research through expert consultation which based on literature research and clinical experience of department preliminary made of therapy, which include implement of CP、the evalution of effection、the evalution of efficiency and the part of perioperative medical treatment. We preliminary determine the surgical selection criteria、the time of using antibiatics、Chinese medicine treatment after surgery、efficacy and efficiency evaluation.
2. With regard to the retrospective study, we determine target population and the exit criteria of path, total path time limit, implement processes of path on the basis of optimized seheme. Also we form path form, according to pathform format issued by the state ministry.
3. The clinical pathway regulates the management of our hospital process, reduces hospital expenses (main reduce the expenses of TAH);shortens hospitalization days, improves patient clinical symptoms; ensure the quality of medical treatment. Explanation of clinical pathway standardized management and strengthen the characteristies of the application.
引文
[1]Myers ER, Barber MD, Gustilo-Ashby T, et al. Management of uterine. leiomyomata:what do we really know? [J]. Obstet Gynecol,2002,100(1):8-17.
[2]许争峰,王迅美.子宫平滑肌瘤细胞遗传学初步研究[J].中华妇产科杂,1993,28(2)：91.
[3]Kurbanora MKH, Koroleva AG, Sergeer AS. Genetic2 cepidemiolgic ana-lysis of uterine myoma:assessment of repeated risk [J]. Genetika,1999,25:1896.
[4]Cook JD, Walker CL. Treatment strategies for uterine leiomyoma:the role of hormonal modulation [J]. Semin Reprod Med,2004,22:105-111.
[5]Wolanska M, Bankowski E. Fibroblast growth factors (FGF) in human myometrium. and uterine leiomyomas in various stages of tumour growth [J]. Biochimie, 2006,88:141-146.
[6]Gamage SD, Bischoff ED, Burroughs KD, et al. Efficacy of LGD 69 (Targretin), aretinoid X receptor- selective ligand,for treatment of uterine leiomyoma [J].J Pharmacol Exp Ther,2009,75:125-128.
[7]Adolfsson PI Haug I, Berg G, et al Changes in beta (2)-a-drenoceptor expression and in adenyly cyclase and phosphodi-esterase activity in human uterine leiomyomas [J]. Mol Hum Reprod,2000,6:835-842.
[8]曹泽毅.中华妇产科学[M]第2版.人民卫生出版社,2004.09：2087-2089.
[9]曹泽毅.中华妇产科学[M]第2版.人民卫生出版社,2004.09：2094.
[10]崔满华.子宫发育异常的分类及诊治[J].实用妇产科杂志,2009,25(9)：518-520.
[11]Berek JS. Berek & Novak妇科学[M].14版.郎景和,向阳,译.北京：人民卫生出版社,2008：302.
[12]Di Lieto A, De Faleo M, Pollio F, et al. Clinical response, vascular change, and angiogenesis in gonadotropin-releasing hormone analogue-treated women with uterine myomas [J]. J Soc Gynecol Investig,2005,12:123-128.
[13]Di Lieto A, De Falco M, Mansueto G, et al. Preoperative administration of GnRH-a plus tibolone to premenopausal women with uterine fibroids: evaluation of the clinical response, the immunohistochemical expression of PDGF, bFGF and VEGF and the vascular pattern[J]. Steroids,2005.70:95-102.
[14]Eisinger SH, Bonfiglio T, Fiscela K, et al. Twelve-month safety and efficacy of low-dose mifepristone for uterine myomas[J]. J Minim Invasive Gyneeol, 2005,12:227-233.
[15]Fiscella K, Eisinger SH, Meldrum S, et al. Efect of mifepristone for symptomatic leiomyomata on quality of life and uterine size:a randomized controlled trial[J]. Obstet Gynecol.2006.108:1381-1387.
[16]Lewis JS, Jordan VC. Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance[J]. Mutat Res,2005, 591:247-263.
[17]苏应宽,徐增祥,江森主编.新编实用妇产科学[M].济南：山东科学技术出版社,1995：376-377.
[18]Ettinger B, Black DM, Mitlak BH, et al。Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation(MORE)Investigators[J]. JAMA,1999,282:637-645.
[19]Jirecek S, Lee A, Pavo 1, et al. Raloxifene prevents the growth of uterine leiomyomas in premenopausal women [J]. Fertil Steril,2004,81:132-136.
[20]Grigorieva V, Chen-Mok M, Tarasova M, et al. Use of a Levonorgestrel-releasing intrauterine system to treat bleeding related to uterine leiomyomas[J]. Fertil Steril,2003,79:1194-1198.
[21]Chwalisz K, Garg R, Brenner R, et al. Role of nonhuman primate models ill the discovery and clinical development of selective progesterone receptor modulators (SPRMs) [J]. Reprod Biol Endocrinol,2006,4:58.
[22]Chwalisz K, Larsen L, Mattia-Goldberg C, et al. A ran-domized, controlled trial of asoprisnil. a novel selective progesterone receptor modulator, in women with uterine leiomyomata[J]. Fertil Steril,2007,87:1399-1412.
[23]Wilkens J, Chwalisz K, Han C, et al. Efects of the selective progesterone receptor modulator asoprisnil on utenne artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy [J]. J Clin Endoerinol Metab,2008 [Epub ahead of print],56 (9): 241.
[24]De Leo V. la Marca A. Morgante G. Short-terma treatment of uterine fibromyomos with danazol. Gynecol Obsetet Invest,1999,47(4):258.
[25]Ronald T, urkman MD. Management of the fibroid uterus. Currntpro blemsin Obstet Gynecol ane Fertil,1998,21(2):31.
[26]Spitz IM, Bardin CW. mifeprestone (Ru486)-A modulator of progestin and glucocorticoid action. N Eng J Med,2010,329:408.
[27]陈常佩,陆兆龄主编.妇产科彩色多普勒诊断学.第1版,北京：人民卫生出版社,1998：43.
[28]Oldenhave A, Jasjmann JB, Everaerde TH et al. Hysterectomized women with ovarian conservation report more severs climacteric complaints that do normal climacteric women of similar age. Am Obstet Gynecol,1993.168:765.
[29]Nezhat Nezhat F, Seidman DS et al. Vaginal vault eviscerationafter total laparoscopic hysterectomy. Obstet Gynecol,1996,87:868.
[30]Storm HH, Clemmensen IH, Manders T et al. Supravaginal uterine—amputation in Denmark 1997—1988 and risk of cancerGynecol Oncol,2010,45:1998.
[31]杨丽,杜建英.子宫次全切除两种不同术式预防宫颈残端癌效果观察.肿瘤防治杂志,2001,8(4)：447.
[32]Dorr CH. Relaxation of pelvic supports In:Gurmt Obstet and Gy-necil Diagnosis and TreatmenL 8th ed Dechemey(editor). Apple-ton and Lange,2010: 825.
[33]周应芳.各种子宫切除术式的评价.中国医刊杂志,2006,41(6)：14.
[34]Sutton C. Subtotal hysterectomy revisited. Endosc Surv Allid Technol, 1995,3 (2～3):105.
[35]黄而弘,欧红等.经阴道和腹腔镜子宫肌瘤剔除术临床对比分析.微创医学,2009,10(4)：525-526.
[36]Harkki P, Kurki T, Sjoberg J, et al. Safety aspects of laparosco-pie hysterectomy. Acta Obstet Gynecol Scand,2010,80 (5):383-391.
[37]权丽丽.腹腔镜辅助阴式子宫切除术临床分析.中国实用医药,2009,9：86-87.
[38]李光仪,陈露诗,黄浩,等.腔镜下子宫切除术治疗子宫肌瘤.1163例临床研究.中国实用妇科与产科杂志,2002,18(3)：184-186.
[39]段丽君.腹腔镜子宫肌瘤剔除术75例工临床分析.腹腔镜外科杂志,2006,11(4)：318-319.
[40]夏恩兰.宫腔镜电切术治疗子宫肌瘤962例疗效分析.中华医学杂志,2005,85(3)：173-176.
[41]杨延林,陈杰,雷巍.宫腔镜严重并发症的发生和救治.实用妇产科杂志,2005,21(7)：401-403.
[42]夏恩兰.介入性超声在官腔镜手术中的应用.中国微创外科杂志,2006,4(6)：248-251.
[43]陈晓明,罗鹏飞.全面认识子宫肌瘤导管栓塞治疗的现状、问题和挑战.介入放射学杂志,2006,15(8)：449-450.
[44]李文敏,黄丽金等.子宫动脉栓塞治疗子宫肌瘤的临床研究.中国医药导报,2010,18：31-32.
[45]邹燕红,任家武.子宫肌瘤动脉栓塞术治疗子宫肌瘤副反应及并发症研究进展.基层医学论坛,2010,13：5588-5589.
[46]林晓丹,石兴源等.经子宫动脉栓塞术治疗子宫肌瘤41例临床研究.中国实用医药,2009,2：11-12.
[47]Uchida T, Baba S, Irie A, et al. Transrectal high-intensity focu-sed ultrasound in the treatment of localized cancer:a multicenter study. Hinyokika Kiyo,2005,51:651-658.
[48]陈亚民,郭慧石等.高强度聚焦超声治疗子宫肌瘤79例临床分析.中国现代医药杂志,2009,4(11)：96-98.
[49]梁萍,董宝玮,董隽,等.超声引导下经皮微波凝固治疗肾肿瘤1例.中华超声影像学杂志,2003,12(7)：445-446.
[50]周翠玉.瘤内注射无水乙醇治疗子宫肌瘤的临床研究.实用妇产科杂志,2006,22(3)：169-170.
[51]李玉洁,王庆志.射频消融联合软坚散结汤治疗子宫肌瘤疗效观察.山东医药,2009,49(30)：66-67.
[52]卢虹,叶春媚,杨进琼,等.超声介导射频治疗子宫肌瘤疗效的分析.临床超声医学杂志,2006,8(9)：562.
[53]张义红,杨连卫.射频消融技术治疗子宫肌瘤致急性肾功能衰竭.中国妇幼保健,2005,20：352.
[54]原田润太,杨友竹.MRI引导下以氩、氦冷冻探针经皮穿刺冷冻法治疗肾癌、肝癌和子宫肌瘤.日本医学介绍,2003,24(2)：51-53.
[55]白广德,谢爱玲,谢桂珍,等.腹腔镜下氩氦刀冷冻消融配合中药治疗子宫肌瘤临床疗效观察.现代中西医结合杂志,2006,15(3)：282-284.
[56]程国昌,何相明.应用氩氦刀治疗子宫肌瘤28例疗效分析.中国妇幼保健,2005,20(22)：3021-3022.
[57]王仙荣,范翠芳,郑德萍,等.腹腔镜下射频消融治疗子宫肌瘤46例临床观察.中国内镜杂志,2006,12(5)：500-502.
[58]曾菲英.刘文苓.肖承棕教授治疗子宫肌瘤经验述要.中医药学刊.2004,22(4)：26-27.
[59]张春玲.中医药在子宫肌瘤围手术期中的应用现状分析[J].中国中医急症,2006,15(8)：907.
[60]王悦.邵亨元辨证论治子宫肌瘤经验举隅[J].江苏中医药,2006,27(12)：12.
[61]李颖,秦淑芳.丹七化瘢胶囊治疗子宫肌瘤临床观察[J.河南中医药学报,2003, 18(3)：39-40.
[62]陆耘,邓志红.化症汤治疗气滞血瘀证子宫肌瘤临床观察[J].安徽中医学院学报,2005,24(6)：16-17.
[63]于涛,曹守伟.化湿散结汤治疗子宫平滑肌瘤30例疗效观察[J].江西中医药,2002,33(5)：23-24.
[64]高月平.从痰瘀论治妇科疾病之机理及其证治浅析[J].中医药学刊,2002,20(4)：486-487.
[65]张秋梅,陈旭.中药袁氏消瘤汤治疗子宫肌瘤临床观察[J].辽宁中医杂志,2007,34(9)：1273.
[66]尤昭玲,王若光,付灵梅.气虚血瘀和益气化瘀法在妇科疾病治疗中的地位和意义[J].湖南中医药导报,2001,7(9)：440-444.
[67]王若光,尤昭玲,郑其昌,等.益气化瘀治疗子宫肌瘤30例[J].中国民间疗法,1999,(10)：44.
[68]齐聪钱,张勤华,黄宗瀚.补肾活血方治疗子宫肌瘤63例临床观察[J].四川中医,2003,21(5)：45-46.
[69]沈宁.沈绍功应用调肾法治疗子宫肌瘤的经验心得[J].中国中医基础医学杂志,2005,11(12)：945.
[70]杨家林.子宫肌瘤的中医治疗[J].实用妇产科杂志,1999,15(2)：66-67.
[71]何增富.少腹逐瘀汤加减治疗子宫肌瘤寒凝血瘀型32例疗效观察[J].云南中医中药杂志,1998,19(2)：27-28.
[72]孔桂茹.滋阴养血法治疗子宫肌瘤的临床探讨[J].青海医药杂志,2006,36(3)：45-46.
[73]陈艳.肖承棕.益气祛瘀法分期治疗子宫肌瘤的临床研究[J].北京中医药大学学报,2002,25(6)：68-70.
[74]王风岭.中医治疗子宫肌瘤30例[J]中国乡村医药杂志,2002,9(11)：21.
[75]肖承宗.补消结合治疗子宫肌瘤[J].新中医,2001,33(10)：3-4.
[76]高玉芬.桂枝茯苓汤加减治疗子宫肌瘤62例[J].河南中医,2004,24(8)：8.
[77]郝瑞芳.桂枝茯苓丸加减治疗子宫肌瘤66例临床观察[J].中国医药指南2009,6(7)：200.
[78]勇华,吕家山.少腹逐瘀汤加味治疗早期子宫肌瘤26例[J].陕西中医,2001,22(6)：360.
[79]杨淮,王洪白.少腹逐瘀汤加减治疗子宫肌瘤37例[J].实用中医药杂志,2006,22(6)：336.
[80]李永琼.逍遥散加味治疗子宫肌瘤78例[J].四川中医,2003,21(12)：57.
[81]杨方,孙金莲.逍遥散加殊治疗子宫肌瘤53例临床分析[J].浙江中西医结合杂 志,2000,10(3)：174.
[82]郝丽艳,杨集群.理冲汤加减治疗子宫肌瘤30例[J].吉林中医药,2000,6：32.
[83]李云端.理冲汤治妇科瘕瘕验案3则[J].国医论坛,2000,15(3)：37.
[84]罗元恺.子宫肌瘤的中医治疗[J].新中医,1992(8)：18.
[85]傅萍,马林.血竭化瘤冲剂治疗子宫肌瘤50例[J].中国中医药科技,2001,8(2)：132-133.
[86]王东红.肖承棕教授运用对药治疗子宫肌瘤经验[J].吉林中医药,2009,9(29)：745-746.
[87]卞福萍,贾士全.桂枝茯苓胶囊治疗子宫肌瘤74例[J].中国中医急症,2008,17(1)：46.
[88]王晓芳.宫瘤清胶囊治疗子宫肌瘤123例疗效分析[J],天津药学,2008,20(5)：43-44.
[89]王天梅.雷公藤多甙片治疗子宫肌瘤的临床观察[J].河南职工医学院学报,2007,19(5)：43.
[90]马哲,段俊成.龙血竭胶囊治疗子宫肌瘤36例临床观察[J].临床医学实践杂志,2003,12(5)：376.
[91]崔文利.复方水蛭胶囊治疗子宫肌瘤临床观察[J].河北中医,2000,6(6)：416.
[92]刘炳权,米建平.针灸治疗子宫肌瘤88例疗效观察[J].针灸临床杂志,2002,18(4)：7-8.
[93]胡振霞.针推结合治疗子宫肌瘤33例[J]. ChineseAcupunc ture&Moxibustion, Oct,2003,23(10):618.
[94]庞保珍,赵焕云.中医药治疗子宫肌瘤的研究进展.中国性科学,2009,18(7)：25-26.
[95]周继喜,皮士舵,孙晋玲.丹参消瘕方灌肠治疗子宫肌瘤60例[J].中国中医药科技,2001,8(5)：317.
[96]李云霞.中药灌肠治疗子宫肌瘤[J].光明中医,2008,23(5)：631.
[97]马丽雅,王金华,高素兰,等.妇疾康阴道给药法治疗子宫肌瘤82例Ⅰ临床研究[J].中国实验方剂学杂志,1999,5(3)：56-57.
[98]辛听.李艳慧.中药穴位贴敷治疗子宫肌瘤30例临床观察.针灸临床杂志,2006,22(7)：15.
[99]裴磊.针刺配合中药治疗子宫肌瘤24例疗效观察[J].湖南中医杂志,2006,22(1)：12-13.
[100]王萍,王黎明,李陵.内外合治子宫肌瘤74例疗效观察[J].中医药导报,2005,11(5)：31-33.
[101]李坤寅,刘宇权,岳炜.运脾饮治疗妇科腹部术后诸症临床观察[J].新中医, 2001,33(8)：18-19
[102]李瑞兰,姜中娟,陈得群等.术后康口服液对剖腹术后排气效果观察.中国中西医结合杂志,1995,15(8)：501-502
[103]陈红阳.中医药结合治疗阑尾穿孔术后肠麻痹28例.中国中西医杂志,1996,16(4)：220.
[104]谢露芬,王月容.剖腹术后加服排气汤200例疗效观察.湖南中医杂志,1995,11(1)：27.
[105]李祥兰,程琪辉,戴建萍.辨证治疗妇科术后胃肠功能恢复不良52例.中医药研究,1996,(6)：26.
[106]吴信受.健脾益气汤治疗术后“脾气虚”的观察.北京中医杂志,1985,(3)：2627.
[107]李国进,沈林森,陈金明等.中药防粘汤预防术后肠粘连疗效观察.中国中医药科技,1997,4(1)：241-242.
[108]周冉.益通汤治疗普外术后综合症.四川中医,2005.23(8)：77.
[109]李燕,王凯.中药排气汤在妇科腹部手术后的应用观察.中医民间疗法,1999,(4)：26.
[110]马刚,姜锡斌等.腹部术后胃肠功能减弱的中医药防治概况.山东中医杂志,2001,20(3)：186-188.
[111]王知佳,郭慧君,张玉华.健脾理气法治疗腹部术后胃肠功能紊乱50例[J].实用中医药杂志,2006,22(10)：624.
[112]龚发军,申巧云.大承气汤对腹部术后胃肠动力障碍的影响.湖南中医药导报,2003,9(6)：42-43.
[113]严绳华,钱道乾.小柴胡汤加昧治疗腹部手术后胃肠功能紊乱72例[J].现代中医药2004；(4)：40-40.
[114]杨东鹰,段绍斌,李广学.“肠气通”颗粒剂促进腹腔术后胃肠功能恢复疗效观察.新疆中医药,2002,20(3)：32-33.
[115]刘本春,高大硕.扶正理气汤直肠滴入对腹部术后胃肠功能恢复的影响.中医外治杂志,2003,12(3)：39.
[116]周艳伟,赵语华,高小玲等.畅舒汤保留灌肠治疗腹部术后胃肠功能紊乱临床观察疗效观察[J].中华实用中西医杂志,2006;19(20)：2475.
[117]杨顺俊,李维蓉,俞荣彩等.扶阳健胃汤保留灌肠促进胃肠癌术后胃肠功能恢复的疗效观察[J].中国医学理论与实践.2007；17(12)：1246.
[118]马朝群,陈德轩,朱永康等.加味暖脐散对手术后胃肠功能的影响[J].中国中西医结合消化杂志.2006：14(5)：328-329.
[119]张珲,钱润芬.生大黄敷脐在阑尾切除术后的应用[J].浙江中西医结合杂志,2007：17(12)：785-786.
[120]房晓宇,陈德轩.针刺足三里对腹部术后胃肠功能的影响[J].中国中西医结合消化杂志.2009：14(5)：328-329.
[121]司呈泉,宿广峰,许振国.针刺足三里对腹部术后胃肠功能的影响[J].中国中西医结合外科杂志,2007：13(6),547-549.
[122]张娅.临床路径的实施及展望[J].解放军护理杂志,2009,26(9B1：36-38.
[123]杜桂珍,刘雁等.临床路径在髋关节置换术患者健康教育中的应用[J].现代临床护理,2009,8(9)：40-42.
[124]张宏雁,董军,秦银河,等.临床路径制定与住院诊疗质量实时控制中的应用.中华医院管理杂志,2002,18：336.
[125]英立平,周保利.北京地区开展临床路径应用研究概述[J].中华医院管理杂志,2007,23(5)：289-292.
[126]Brunenberg DE, vanSteyn MJ, Sluimer JC, et al. Joint recovery programme versus usual care:all economic evaluation of a clinical pathway for joint replacement surgery [J]. MedCare,2005,43(10):1018.
[127]黄惠根.德国护理行业的变革对我国护理事业的启示[J].护理管理,2006(2)：36.
[128]骆海燕.临床路径在我国的应用及其进展[J].家庭护士.2007,5(8)53-56.
[129]邱风兰,段涛.临床路径在腹腔镜胆囊切除手术病人应用探讨[J].医学信息,2009,8(22)：41-42.
[130]李晓芳,张永生.浅谈临床路径的实施和发展趋势FJ].解放军医院管理杂志,2004,11(1)：40-42.
[131]张力斌.临床路径的组织实施[J].医疗管理,2003,23(11)：23-24.
[132]Lin F, Chou S. Mining time dependency patterns in clinical pathways [J]. Int J Med Inf,2001,62:11-25.
[133]天原.临床路径的实施与测评-科学管理的现实实施方式[J].当代医学,2003,(11)：29-30.
[134]叶茂.应用层次分析法评价医院临床科室的综合绩效[J].中国医院,2005,9(8)：58-60.
[135]袁剑云,英立平.临床路径实施手册[M].北京：北京医科大学、中国协和医科大学联合出版社,2002：4.
[136]董叶丽.新加坡樟宜综合医院的临床路径[J].中华护理杂志,2002,37(7)：560.
[137]高艳红.临床路径在科室护理质量监控中的应用[J]. CHINESE NURSING RESEARCH,2009,23(7A):1764-1765.
[138]黄敬亨.健康教育学[M].上海：上海医科大学出版社,1997.212.
[139]袁方.社会研究方法教程[M].北京：北京大学出版社,1997；234-235.
[140]方积乾.医学统计学与电脑实验[M].第2版.上海：上海科学技术出版社,2001：449-457.
[141]李俊漩,白玫,刘华平,等.Delphi法在护理岗位任务分析及人才需求预测研究中的应用[J].护理管理杂志,2004,4(6)：35-37.
[142]郭松芹.胆囊剔除术病人住院费用及相关因素分析[J].卫生经济研究,2004,4：30-31.
[143]潘宗华.骨科手术前期病人的健康教育和心理护理[J].医药论坛杂志,2005,26(21)： 94.
[144]于兆莉.老年人住院期间不安全因素及防护对策[J].医药论坛杂志,2005,25(18)：82.
[145]市川几惠.临床路径在日本的应用[J].国外医学护理分册,2002,21(8)：373-374.
[146]季一鸣,罗文达,褚江洪.临床路径推广难点分析[J].中国卫生质量管理,2005,12(5)：20-21.
[2]许争峰,王迅美.子宫平滑肌瘤细胞遗传学初步研究[J].中华妇产科杂,1993,28(2)：91.
[3]Kurbanora MKH, Koroleva AG, Sergeer AS. Genetic2 cepidemiolgic ana-lysis of uterine myoma:assessment of repeated risk [J]. Genetika,1999,25:1896.
[4]Cook JD, Walker CL. Treatment strategies for uterine leiomyoma:the role of hormonal modulation [J]. Semin Reprod Med,2004,22:105-111.
[5]Wolanska M, Bankowski E. Fibroblast growth factors (FGF) in human myometrium. and uterine leiomyomas in various stages of tumour growth [J]. Biochimie, 2006,88:141-146.
[6]Gamage SD, Bischoff ED, Burroughs KD, et al. Efficacy of LGD 69 (Targretin), aretinoid X receptor- selective ligand,for treatment of uterine leiomyoma [J].J Pharmacol Exp Ther,2009,75:125-128.
[7]Adolfsson PI Haug I, Berg G, et al Changes in beta (2)-a-drenoceptor expression and in adenyly cyclase and phosphodi-esterase activity in human uterine leiomyomas [J]. Mol Hum Reprod,2000,6:835-842.
[8]曹泽毅.中华妇产科学[M]第2版.人民卫生出版社,2004.09：2087-2089.
[9]曹泽毅.中华妇产科学[M]第2版.人民卫生出版社,2004.09：2094.
[10]崔满华.子宫发育异常的分类及诊治[J].实用妇产科杂志,2009,25(9)：518-520.
[11]Berek JS. Berek & Novak妇科学[M].14版.郎景和,向阳,译.北京：人民卫生出版社,2008：302.
[12]Di Lieto A, De Faleo M, Pollio F, et al. Clinical response, vascular change, and angiogenesis in gonadotropin-releasing hormone analogue-treated women with uterine myomas [J]. J Soc Gynecol Investig,2005,12:123-128.
[13]Di Lieto A, De Falco M, Mansueto G, et al. Preoperative administration of GnRH-a plus tibolone to premenopausal women with uterine fibroids: evaluation of the clinical response, the immunohistochemical expression of PDGF, bFGF and VEGF and the vascular pattern[J]. Steroids,2005.70:95-102.
[14]Eisinger SH, Bonfiglio T, Fiscela K, et al. Twelve-month safety and efficacy of low-dose mifepristone for uterine myomas[J]. J Minim Invasive Gyneeol, 2005,12:227-233.
[15]Fiscella K, Eisinger SH, Meldrum S, et al. Efect of mifepristone for symptomatic leiomyomata on quality of life and uterine size:a randomized controlled trial[J]. Obstet Gynecol.2006.108:1381-1387.
[16]Lewis JS, Jordan VC. Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance[J]. Mutat Res,2005, 591:247-263.
[17]苏应宽,徐增祥,江森主编.新编实用妇产科学[M].济南：山东科学技术出版社,1995：376-377.
[18]Ettinger B, Black DM, Mitlak BH, et al。Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation(MORE)Investigators[J]. JAMA,1999,282:637-645.
[19]Jirecek S, Lee A, Pavo 1, et al. Raloxifene prevents the growth of uterine leiomyomas in premenopausal women [J]. Fertil Steril,2004,81:132-136.
[20]Grigorieva V, Chen-Mok M, Tarasova M, et al. Use of a Levonorgestrel-releasing intrauterine system to treat bleeding related to uterine leiomyomas[J]. Fertil Steril,2003,79:1194-1198.
[21]Chwalisz K, Garg R, Brenner R, et al. Role of nonhuman primate models ill the discovery and clinical development of selective progesterone receptor modulators (SPRMs) [J]. Reprod Biol Endocrinol,2006,4:58.
[22]Chwalisz K, Larsen L, Mattia-Goldberg C, et al. A ran-domized, controlled trial of asoprisnil. a novel selective progesterone receptor modulator, in women with uterine leiomyomata[J]. Fertil Steril,2007,87:1399-1412.
[23]Wilkens J, Chwalisz K, Han C, et al. Efects of the selective progesterone receptor modulator asoprisnil on utenne artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy [J]. J Clin Endoerinol Metab,2008 [Epub ahead of print],56 (9): 241.
[24]De Leo V. la Marca A. Morgante G. Short-terma treatment of uterine fibromyomos with danazol. Gynecol Obsetet Invest,1999,47(4):258.
[25]Ronald T, urkman MD. Management of the fibroid uterus. Currntpro blemsin Obstet Gynecol ane Fertil,1998,21(2):31.
[26]Spitz IM, Bardin CW. mifeprestone (Ru486)-A modulator of progestin and glucocorticoid action. N Eng J Med,2010,329:408.
[27]陈常佩,陆兆龄主编.妇产科彩色多普勒诊断学.第1版,北京：人民卫生出版社,1998：43.
[28]Oldenhave A, Jasjmann JB, Everaerde TH et al. Hysterectomized women with ovarian conservation report more severs climacteric complaints that do normal climacteric women of similar age. Am Obstet Gynecol,1993.168:765.
[29]Nezhat Nezhat F, Seidman DS et al. Vaginal vault eviscerationafter total laparoscopic hysterectomy. Obstet Gynecol,1996,87:868.
[30]Storm HH, Clemmensen IH, Manders T et al. Supravaginal uterine—amputation in Denmark 1997—1988 and risk of cancerGynecol Oncol,2010,45:1998.
[31]杨丽,杜建英.子宫次全切除两种不同术式预防宫颈残端癌效果观察.肿瘤防治杂志,2001,8(4)：447.
[32]Dorr CH. Relaxation of pelvic supports In:Gurmt Obstet and Gy-necil Diagnosis and TreatmenL 8th ed Dechemey(editor). Apple-ton and Lange,2010: 825.
[33]周应芳.各种子宫切除术式的评价.中国医刊杂志,2006,41(6)：14.
[34]Sutton C. Subtotal hysterectomy revisited. Endosc Surv Allid Technol, 1995,3 (2～3):105.
[35]黄而弘,欧红等.经阴道和腹腔镜子宫肌瘤剔除术临床对比分析.微创医学,2009,10(4)：525-526.
[36]Harkki P, Kurki T, Sjoberg J, et al. Safety aspects of laparosco-pie hysterectomy. Acta Obstet Gynecol Scand,2010,80 (5):383-391.
[37]权丽丽.腹腔镜辅助阴式子宫切除术临床分析.中国实用医药,2009,9：86-87.
[38]李光仪,陈露诗,黄浩,等.腔镜下子宫切除术治疗子宫肌瘤.1163例临床研究.中国实用妇科与产科杂志,2002,18(3)：184-186.
[39]段丽君.腹腔镜子宫肌瘤剔除术75例工临床分析.腹腔镜外科杂志,2006,11(4)：318-319.
[40]夏恩兰.宫腔镜电切术治疗子宫肌瘤962例疗效分析.中华医学杂志,2005,85(3)：173-176.
[41]杨延林,陈杰,雷巍.宫腔镜严重并发症的发生和救治.实用妇产科杂志,2005,21(7)：401-403.
[42]夏恩兰.介入性超声在官腔镜手术中的应用.中国微创外科杂志,2006,4(6)：248-251.
[43]陈晓明,罗鹏飞.全面认识子宫肌瘤导管栓塞治疗的现状、问题和挑战.介入放射学杂志,2006,15(8)：449-450.
[44]李文敏,黄丽金等.子宫动脉栓塞治疗子宫肌瘤的临床研究.中国医药导报,2010,18：31-32.
[45]邹燕红,任家武.子宫肌瘤动脉栓塞术治疗子宫肌瘤副反应及并发症研究进展.基层医学论坛,2010,13：5588-5589.
[46]林晓丹,石兴源等.经子宫动脉栓塞术治疗子宫肌瘤41例临床研究.中国实用医药,2009,2：11-12.
[47]Uchida T, Baba S, Irie A, et al. Transrectal high-intensity focu-sed ultrasound in the treatment of localized cancer:a multicenter study. Hinyokika Kiyo,2005,51:651-658.
[48]陈亚民,郭慧石等.高强度聚焦超声治疗子宫肌瘤79例临床分析.中国现代医药杂志,2009,4(11)：96-98.
[49]梁萍,董宝玮,董隽,等.超声引导下经皮微波凝固治疗肾肿瘤1例.中华超声影像学杂志,2003,12(7)：445-446.
[50]周翠玉.瘤内注射无水乙醇治疗子宫肌瘤的临床研究.实用妇产科杂志,2006,22(3)：169-170.
[51]李玉洁,王庆志.射频消融联合软坚散结汤治疗子宫肌瘤疗效观察.山东医药,2009,49(30)：66-67.
[52]卢虹,叶春媚,杨进琼,等.超声介导射频治疗子宫肌瘤疗效的分析.临床超声医学杂志,2006,8(9)：562.
[53]张义红,杨连卫.射频消融技术治疗子宫肌瘤致急性肾功能衰竭.中国妇幼保健,2005,20：352.
[54]原田润太,杨友竹.MRI引导下以氩、氦冷冻探针经皮穿刺冷冻法治疗肾癌、肝癌和子宫肌瘤.日本医学介绍,2003,24(2)：51-53.
[55]白广德,谢爱玲,谢桂珍,等.腹腔镜下氩氦刀冷冻消融配合中药治疗子宫肌瘤临床疗效观察.现代中西医结合杂志,2006,15(3)：282-284.
[56]程国昌,何相明.应用氩氦刀治疗子宫肌瘤28例疗效分析.中国妇幼保健,2005,20(22)：3021-3022.
[57]王仙荣,范翠芳,郑德萍,等.腹腔镜下射频消融治疗子宫肌瘤46例临床观察.中国内镜杂志,2006,12(5)：500-502.
[58]曾菲英.刘文苓.肖承棕教授治疗子宫肌瘤经验述要.中医药学刊.2004,22(4)：26-27.
[59]张春玲.中医药在子宫肌瘤围手术期中的应用现状分析[J].中国中医急症,2006,15(8)：907.
[60]王悦.邵亨元辨证论治子宫肌瘤经验举隅[J].江苏中医药,2006,27(12)：12.
[61]李颖,秦淑芳.丹七化瘢胶囊治疗子宫肌瘤临床观察[J.河南中医药学报,2003, 18(3)：39-40.
[62]陆耘,邓志红.化症汤治疗气滞血瘀证子宫肌瘤临床观察[J].安徽中医学院学报,2005,24(6)：16-17.
[63]于涛,曹守伟.化湿散结汤治疗子宫平滑肌瘤30例疗效观察[J].江西中医药,2002,33(5)：23-24.
[64]高月平.从痰瘀论治妇科疾病之机理及其证治浅析[J].中医药学刊,2002,20(4)：486-487.
[65]张秋梅,陈旭.中药袁氏消瘤汤治疗子宫肌瘤临床观察[J].辽宁中医杂志,2007,34(9)：1273.
[66]尤昭玲,王若光,付灵梅.气虚血瘀和益气化瘀法在妇科疾病治疗中的地位和意义[J].湖南中医药导报,2001,7(9)：440-444.
[67]王若光,尤昭玲,郑其昌,等.益气化瘀治疗子宫肌瘤30例[J].中国民间疗法,1999,(10)：44.
[68]齐聪钱,张勤华,黄宗瀚.补肾活血方治疗子宫肌瘤63例临床观察[J].四川中医,2003,21(5)：45-46.
[69]沈宁.沈绍功应用调肾法治疗子宫肌瘤的经验心得[J].中国中医基础医学杂志,2005,11(12)：945.
[70]杨家林.子宫肌瘤的中医治疗[J].实用妇产科杂志,1999,15(2)：66-67.
[71]何增富.少腹逐瘀汤加减治疗子宫肌瘤寒凝血瘀型32例疗效观察[J].云南中医中药杂志,1998,19(2)：27-28.
[72]孔桂茹.滋阴养血法治疗子宫肌瘤的临床探讨[J].青海医药杂志,2006,36(3)：45-46.
[73]陈艳.肖承棕.益气祛瘀法分期治疗子宫肌瘤的临床研究[J].北京中医药大学学报,2002,25(6)：68-70.
[74]王风岭.中医治疗子宫肌瘤30例[J]中国乡村医药杂志,2002,9(11)：21.
[75]肖承宗.补消结合治疗子宫肌瘤[J].新中医,2001,33(10)：3-4.
[76]高玉芬.桂枝茯苓汤加减治疗子宫肌瘤62例[J].河南中医,2004,24(8)：8.
[77]郝瑞芳.桂枝茯苓丸加减治疗子宫肌瘤66例临床观察[J].中国医药指南2009,6(7)：200.
[78]勇华,吕家山.少腹逐瘀汤加味治疗早期子宫肌瘤26例[J].陕西中医,2001,22(6)：360.
[79]杨淮,王洪白.少腹逐瘀汤加减治疗子宫肌瘤37例[J].实用中医药杂志,2006,22(6)：336.
[80]李永琼.逍遥散加味治疗子宫肌瘤78例[J].四川中医,2003,21(12)：57.
[81]杨方,孙金莲.逍遥散加殊治疗子宫肌瘤53例临床分析[J].浙江中西医结合杂 志,2000,10(3)：174.
[82]郝丽艳,杨集群.理冲汤加减治疗子宫肌瘤30例[J].吉林中医药,2000,6：32.
[83]李云端.理冲汤治妇科瘕瘕验案3则[J].国医论坛,2000,15(3)：37.
[84]罗元恺.子宫肌瘤的中医治疗[J].新中医,1992(8)：18.
[85]傅萍,马林.血竭化瘤冲剂治疗子宫肌瘤50例[J].中国中医药科技,2001,8(2)：132-133.
[86]王东红.肖承棕教授运用对药治疗子宫肌瘤经验[J].吉林中医药,2009,9(29)：745-746.
[87]卞福萍,贾士全.桂枝茯苓胶囊治疗子宫肌瘤74例[J].中国中医急症,2008,17(1)：46.
[88]王晓芳.宫瘤清胶囊治疗子宫肌瘤123例疗效分析[J],天津药学,2008,20(5)：43-44.
[89]王天梅.雷公藤多甙片治疗子宫肌瘤的临床观察[J].河南职工医学院学报,2007,19(5)：43.
[90]马哲,段俊成.龙血竭胶囊治疗子宫肌瘤36例临床观察[J].临床医学实践杂志,2003,12(5)：376.
[91]崔文利.复方水蛭胶囊治疗子宫肌瘤临床观察[J].河北中医,2000,6(6)：416.
[92]刘炳权,米建平.针灸治疗子宫肌瘤88例疗效观察[J].针灸临床杂志,2002,18(4)：7-8.
[93]胡振霞.针推结合治疗子宫肌瘤33例[J]. ChineseAcupunc ture&Moxibustion, Oct,2003,23(10):618.
[94]庞保珍,赵焕云.中医药治疗子宫肌瘤的研究进展.中国性科学,2009,18(7)：25-26.
[95]周继喜,皮士舵,孙晋玲.丹参消瘕方灌肠治疗子宫肌瘤60例[J].中国中医药科技,2001,8(5)：317.
[96]李云霞.中药灌肠治疗子宫肌瘤[J].光明中医,2008,23(5)：631.
[97]马丽雅,王金华,高素兰,等.妇疾康阴道给药法治疗子宫肌瘤82例Ⅰ临床研究[J].中国实验方剂学杂志,1999,5(3)：56-57.
[98]辛听.李艳慧.中药穴位贴敷治疗子宫肌瘤30例临床观察.针灸临床杂志,2006,22(7)：15.
[99]裴磊.针刺配合中药治疗子宫肌瘤24例疗效观察[J].湖南中医杂志,2006,22(1)：12-13.
[100]王萍,王黎明,李陵.内外合治子宫肌瘤74例疗效观察[J].中医药导报,2005,11(5)：31-33.
[101]李坤寅,刘宇权,岳炜.运脾饮治疗妇科腹部术后诸症临床观察[J].新中医, 2001,33(8)：18-19
[102]李瑞兰,姜中娟,陈得群等.术后康口服液对剖腹术后排气效果观察.中国中西医结合杂志,1995,15(8)：501-502
[103]陈红阳.中医药结合治疗阑尾穿孔术后肠麻痹28例.中国中西医杂志,1996,16(4)：220.
[104]谢露芬,王月容.剖腹术后加服排气汤200例疗效观察.湖南中医杂志,1995,11(1)：27.
[105]李祥兰,程琪辉,戴建萍.辨证治疗妇科术后胃肠功能恢复不良52例.中医药研究,1996,(6)：26.
[106]吴信受.健脾益气汤治疗术后“脾气虚”的观察.北京中医杂志,1985,(3)：2627.
[107]李国进,沈林森,陈金明等.中药防粘汤预防术后肠粘连疗效观察.中国中医药科技,1997,4(1)：241-242.
[108]周冉.益通汤治疗普外术后综合症.四川中医,2005.23(8)：77.
[109]李燕,王凯.中药排气汤在妇科腹部手术后的应用观察.中医民间疗法,1999,(4)：26.
[110]马刚,姜锡斌等.腹部术后胃肠功能减弱的中医药防治概况.山东中医杂志,2001,20(3)：186-188.
[111]王知佳,郭慧君,张玉华.健脾理气法治疗腹部术后胃肠功能紊乱50例[J].实用中医药杂志,2006,22(10)：624.
[112]龚发军,申巧云.大承气汤对腹部术后胃肠动力障碍的影响.湖南中医药导报,2003,9(6)：42-43.
[113]严绳华,钱道乾.小柴胡汤加昧治疗腹部手术后胃肠功能紊乱72例[J].现代中医药2004；(4)：40-40.
[114]杨东鹰,段绍斌,李广学.“肠气通”颗粒剂促进腹腔术后胃肠功能恢复疗效观察.新疆中医药,2002,20(3)：32-33.
[115]刘本春,高大硕.扶正理气汤直肠滴入对腹部术后胃肠功能恢复的影响.中医外治杂志,2003,12(3)：39.
[116]周艳伟,赵语华,高小玲等.畅舒汤保留灌肠治疗腹部术后胃肠功能紊乱临床观察疗效观察[J].中华实用中西医杂志,2006;19(20)：2475.
[117]杨顺俊,李维蓉,俞荣彩等.扶阳健胃汤保留灌肠促进胃肠癌术后胃肠功能恢复的疗效观察[J].中国医学理论与实践.2007；17(12)：1246.
[118]马朝群,陈德轩,朱永康等.加味暖脐散对手术后胃肠功能的影响[J].中国中西医结合消化杂志.2006：14(5)：328-329.
[119]张珲,钱润芬.生大黄敷脐在阑尾切除术后的应用[J].浙江中西医结合杂志,2007：17(12)：785-786.
[120]房晓宇,陈德轩.针刺足三里对腹部术后胃肠功能的影响[J].中国中西医结合消化杂志.2009：14(5)：328-329.
[121]司呈泉,宿广峰,许振国.针刺足三里对腹部术后胃肠功能的影响[J].中国中西医结合外科杂志,2007：13(6),547-549.
[122]张娅.临床路径的实施及展望[J].解放军护理杂志,2009,26(9B1：36-38.
[123]杜桂珍,刘雁等.临床路径在髋关节置换术患者健康教育中的应用[J].现代临床护理,2009,8(9)：40-42.
[124]张宏雁,董军,秦银河,等.临床路径制定与住院诊疗质量实时控制中的应用.中华医院管理杂志,2002,18：336.
[125]英立平,周保利.北京地区开展临床路径应用研究概述[J].中华医院管理杂志,2007,23(5)：289-292.
[126]Brunenberg DE, vanSteyn MJ, Sluimer JC, et al. Joint recovery programme versus usual care:all economic evaluation of a clinical pathway for joint replacement surgery [J]. MedCare,2005,43(10):1018.
[127]黄惠根.德国护理行业的变革对我国护理事业的启示[J].护理管理,2006(2)：36.
[128]骆海燕.临床路径在我国的应用及其进展[J].家庭护士.2007,5(8)53-56.
[129]邱风兰,段涛.临床路径在腹腔镜胆囊切除手术病人应用探讨[J].医学信息,2009,8(22)：41-42.
[130]李晓芳,张永生.浅谈临床路径的实施和发展趋势FJ].解放军医院管理杂志,2004,11(1)：40-42.
[131]张力斌.临床路径的组织实施[J].医疗管理,2003,23(11)：23-24.
[132]Lin F, Chou S. Mining time dependency patterns in clinical pathways [J]. Int J Med Inf,2001,62:11-25.
[133]天原.临床路径的实施与测评-科学管理的现实实施方式[J].当代医学,2003,(11)：29-30.
[134]叶茂.应用层次分析法评价医院临床科室的综合绩效[J].中国医院,2005,9(8)：58-60.
[135]袁剑云,英立平.临床路径实施手册[M].北京：北京医科大学、中国协和医科大学联合出版社,2002：4.
[136]董叶丽.新加坡樟宜综合医院的临床路径[J].中华护理杂志,2002,37(7)：560.
[137]高艳红.临床路径在科室护理质量监控中的应用[J]. CHINESE NURSING RESEARCH,2009,23(7A):1764-1765.
[138]黄敬亨.健康教育学[M].上海：上海医科大学出版社,1997.212.
[139]袁方.社会研究方法教程[M].北京：北京大学出版社,1997；234-235.
[140]方积乾.医学统计学与电脑实验[M].第2版.上海：上海科学技术出版社,2001：449-457.
[141]李俊漩,白玫,刘华平,等.Delphi法在护理岗位任务分析及人才需求预测研究中的应用[J].护理管理杂志,2004,4(6)：35-37.
[142]郭松芹.胆囊剔除术病人住院费用及相关因素分析[J].卫生经济研究,2004,4：30-31.
[143]潘宗华.骨科手术前期病人的健康教育和心理护理[J].医药论坛杂志,2005,26(21)： 94.
[144]于兆莉.老年人住院期间不安全因素及防护对策[J].医药论坛杂志,2005,25(18)：82.
[145]市川几惠.临床路径在日本的应用[J].国外医学护理分册,2002,21(8)：373-374.
[146]季一鸣,罗文达,褚江洪.临床路径推广难点分析[J].中国卫生质量管理,2005,12(5)：20-21.